Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Valtis YK, Devlin S, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I, Schöder H, Bedmutha A, Boardman A, Shah GL, Scordo M, Perales MA, Salles G, Palomba ML, Shah UA, Park JH. Valtis YK, et al. Among authors: palomba ml. Blood Adv. 2025 Jan 14;9(1):151-161. doi: 10.1182/bloodadvances.2024014555. Blood Adv. 2025. PMID: 39471490
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Moskowitz CH, et al. Among authors: palomba ml. J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8. J Clin Oncol. 2010. PMID: 20212248 Free PMC article.
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: palomba ml. J Clin Oncol. 2013 Feb 1;31(4):456-60. doi: 10.1200/JCO.2012.45.3308. Epub 2012 Dec 17. J Clin Oncol. 2013. PMID: 23248254 Free PMC article. Clinical Trial.
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. Moskowitz AJ, et al. Among authors: palomba ml. Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13. Lancet Oncol. 2015. PMID: 25683846 Clinical Trial.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Kumar A, et al. Among authors: palomba ml. Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25. Blood. 2016. PMID: 27458003 Free PMC article.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: palomba ml. Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5. Blood. 2017. PMID: 28874350 Free PMC article.
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH. Sauter CS, et al. Among authors: palomba ml. Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31. Blood. 2018. PMID: 29386196 Free PMC article. Clinical Trial.
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ. Geyer MB, et al. Among authors: palomba ml. JCI Insight. 2019 Apr 2;5(9):e122627. doi: 10.1172/jci.insight.122627. JCI Insight. 2019. PMID: 30938714 Free PMC article. Clinical Trial.
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Lin RJ, Lobaugh SM, Pennisi M, Chan HT, Batlevi Y, Ruiz JD, Elko TA, Maloy MA, Batlevi CL, Dahi PB, Giralt SA, Hamlin PA, Mead E, Noy A, Palomba ML, Santomasso BD, Sauter CS, Scordo M, Shah GL, Korc-Grodzicki B, Kim SJ, Silverberg ML, Brooklyn CA, Devlin SM, Perales MA. Lin RJ, et al. Among authors: palomba ml. Haematologica. 2021 Jan 1;106(1):255-258. doi: 10.3324/haematol.2019.243246. Haematologica. 2021. PMID: 32079691 Free PMC article. No abstract available.
132 results